Anne‐Marie C. Dingemans

This study evaluates the clinical feasibility of evolutionary therapy for NSCLC by simulating its performance under real-world constraints like measurement error and appointment delays.

This study uses deep reinforcement learning to design treatment protocols for NSCLC that improve robustness, quality of life, and time to progression compared to standard adaptive therapy and maximum tolerable dose approaches.

This study validates a pan-cancer NGS assay for liquid biopsy testing across multiple centers, showing high sensitivity and specificity for detecting genomic alterations in cfDNA.